Research Evidence / Overview of Studies for Keppra
This section provides a summary of the clinical research conducted for levetiracetam, focusing strictly on the design of the regulatory trials and the patterns observed, without offering clinical guidance or making claims about individual outcomes.
Evidence Supporting Use in Partial-Onset (Focal) Seizures
The core research for partial-onset seizures, sometimes called focal seizures, involves multiple randomized, double-blind, placebo-controlled trials (RCTs). These short-term studies utilize the most stringent methodological control for gathering initial evidence. Levetiracetam was primarily evaluated as an adjunctive treatment, meaning it was added to a patient’s existing seizure medications.
What Researchers Studied: Researchers monitored cohorts of adults, adolescents, and children (≥ 4 years) who had partial-onset seizures that were not fully controlled by existing medications. The main focus was on outcomes describing episodic or acute changes in seizure frequency. Specifically, studies tracked the average weekly number of partial seizures and the proportion of patients who experienced a 50% or greater reduction in this frequency over short periods, typically around 12 to 18 weeks.
What the Studies Reported: Studies reported measurements showing a change in the median weekly partial seizure frequency in the levetiracetam-treated groups compared to the placebo groups over the study duration. Researchers also reported that the proportion of patients who achieved a ≥ 50% reduction in weekly partial seizure frequency was recorded differently between the groups. These findings describe patterns observed in the studies and contributed to the broader evidence landscape for the use of levetiracetam as an adjunctive therapy in this population.
Evidence Supporting Use in Primary Generalized Tonic-Clonic and Myoclonic Seizures
Dedicated research studies have also examined levetiracetam for generalized seizure types, including Primary Generalized Tonic-Clonic Seizures (PGTCS) and Myoclonic Seizures, which are characteristic of conditions involving periods of heightened symptoms like Idiopathic Generalized Epilepsy (IGE).
Myoclonic Seizures (JME): A key placebo-controlled RCT was conducted in adolescents and adults (≥ 12 years) diagnosed with Juvenile Myoclonic Epilepsy (JME). Research examined outcomes related to episodic or acute changes in seizure activity, primarily measuring the change in the frequency of myoclonic seizure days per week. Findings indicated a change in myoclonic seizure days for the groups studied during the short-term evaluation period.
Primary Generalized Tonic-Clonic Seizures (PGTCS): For PGTCS, studies monitored cohorts of patients (≥ 6 years) who continued to experience these seizures. Researchers used short-term, controlled trial designs to monitor the percent change in GTC seizure frequency per week. Studies reported that the frequency of GTC seizures evolved differently in the groups studied over the evaluation period. Additionally, the proportion of patients documented as achieving a ≥ 50% reduction in weekly GTC seizures was reported differently between the groups.
Evidence in Pediatric and Special Populations
Evidence in special populations is crucial for fully understanding the research context of levetiracetam.
Pediatric Cohorts: Levetiracetam was evaluated in pediatric patients, including children as young as four years old, for partial-onset seizures. Studies examined patient-reported outcomes describing perceived discomfort and changes in seizure patterns in children compared to placebo. A dedicated, small-scale RCT was also performed in children as young as one month to less than four years with refractory partial-onset seizures, applying age-related measurements. For generalized seizures, research also included adolescents and younger children (down to six years old) with PGTCS. Comparative evidence against other treatments in children, particularly for long-term use, remains limited.
Post-Surgical Prophylaxis: Levetiracetam was studied for use in seizure prevention following brain tumor surgery (prophylaxis). Research here often consists of smaller comparative trials and systematic reviews, which sometimes show mixed findings. This research highlights changes measured during the study period, but results were heterogeneous across studies, and dedicated, large-scale, placebo-controlled trials are limited.
Long-Term Research and Durability of Effect
The main initial controlled trials supporting regulatory approval focused on short-term changes in seizure frequency, typically lasting only a few months. However, epilepsy is a chronic condition, requiring exploration of long-term treatment patterns.
Follow-up Studies: To address long-term patterns, many short-term trials transition into long-term open-label extension studies where all patients receive levetiracetam, sometimes for several years. These studies monitor the percentage of patients who continue taking the medication (retention rate) and track patterns in seizure frequency over extended periods.
What Remains Uncertain: Because these follow-up studies are not randomized or placebo-controlled, the observed long-term patterns are not established by the same rigorous standards as the short-term controlled data. Findings describe patterns observed in the studies, suggesting that retention rates—the percentage of patients who continued using the medication—were tracked for several years in these follow-up cohorts. These studies contribute to the broader evidence landscape but reflect the specific conditions under which they were conducted.
What Is Still Uncertain: Research Gaps and Limitations
While a significant amount of research exists, certain limitations and areas of uncertainty are consistently noted in the scientific literature regarding levetiracetam.
- Limited Comparative Evidence: For several indications, particularly in newer epilepsy syndromes, comparative evidence is lacking against other established AEDs, meaning randomized trials comparing levetiracetam to all other standards of care are not always available.
- Long-Term Data Quality: As mentioned, the fixed-duration research is limited to the short-term treatment period in controlled trials. Long-term outcomes related to durability and sustainability are predominantly derived from open-label data, where certainty remains low regarding the direct impact of the medication alone.
- Refractory vs. Newly Diagnosed: Many of the foundational studies focused on patients whose seizures were already refractory (uncontrolled) despite prior treatment. While later research has explored use in newly diagnosed patients (monotherapy), results apply only to the populations studied in the initial trials.
